Essential Properties Realty Trust, Inc. (EPRT)

Intercept Pharmaceuticals Stock Forecast

Stock Price Forecast

The 13 analysts that cover Intercept Pharmaceuticals stock have a consensus rating of "Buy" and an average price target of $34.83, which forecasts a 13.27% increase in the stock price over the next year. The lowest target is $33 and the highest is $38.

Price Target: $34.83 (+13.27%)

Analyst Consensus: Buy

Target	Low	Average	Median	High
Price	$33	$34.83	$34	$38
Change	+7.32%	+13.27%	+10.57%	+23.58%

Analyst Ratings

The average analyst rating for Intercept Pharmaceuticals stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

Rating	Feb '25	Mar '25	Apr '25	May '25	Jun '25	Jul '25
Strong Buy	6	6	6	5	5	4
Buy	6	6	6	6	6	6
Hold	3	3	3	3	3	3
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	15	15	15	14	14	13

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Richard Hightower Barclays	Barclays	Buy Maintains $37 → $36	Buy	Maintains	$37 → $36	+17.07%	Jul 21, 2025
Michael Goldsmith UBS	UBS	Strong Buy Maintains $37 → $36	Strong Buy	Maintains	$37 → $36	+17.07%	Jul 16, 2025
Richard Hightower Barclays	Barclays	Buy Maintains $35 → $37	Buy	Maintains	$35 → $37	+20.33%	May 21, 2025
Michael Goldsmith UBS	UBS	Strong Buy Maintains $40 → $37	Strong Buy	Maintains	$40 → $37	+20.33%	May 13, 2025
Greg McGinniss Scotiabank	Scotiabank	Hold Maintains $32 → $33	Hold	Maintains	$32 → $33	+7.32%	May 12, 2025

More Analyst Ratings

Financial Forecast

Revenue This Year

550.08M

Increased by 22.35%

from 449.61M

Revenue Next Year

642.39M

Increased by 16.78%

from 550.08M

EPS This Year

1.28

Increased by 11.45%

from 1.15

EPS Next Year

1.37

Increased by 7.05%

from 1.28

Fiscal Year	FY 2020	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026	FY 2027
Period Ending	Dec 31, 2020	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026	Dec 31, 2027
Revenue	164.01M	230.23M	286.51M	359.60M	449.61M	550.08M	642.39M	741.87M
Revenue Growth	17.69%	40.38%	24.44%	25.51%	25.03%	22.35%	16.78%	15.49%
EPS	0.44	0.82	0.99	1.24	1.15	1.28	1.37	1.42
EPS Growth	-30.62%	86.44%	21.15%	25.80%	-7.80%	11.45%	7.05%	3.60%
Forward PE	-	-	-	-	-	24.05	22.47	21.69
No. Analysts	-	-	-	-	-	8	8	6

Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue	2025	2026	2027	2028	2029
High	585.3M	690.2M	800.4M
Avg	550.1M	642.4M	741.9M
Low	493.2M	557.5M	667.3M

Revenue Growth

Revenue Growth	2025	2026	2027	2028	2029
High	30.2%	25.5%	24.6%
Avg	22.3%	16.8%	15.5%
Low	9.7%	1.4%	3.9%

EPS Forecast

EPS	2025	2026	2027	2028	2029
High	1.33	1.45	1.54
Avg	1.28	1.37	1.42
Low	1.22	1.25	1.28

EPS Growth

EPS Growth	2025	2026	2027	2028	2029
High	16.3%	13.3%	12.8%
Avg	11.4%	7.0%	3.6%
Low	5.9%	-1.9%	-6.2%

Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.